London
Roots Analysis has announced the
addition of “Targeted Protein Degradation Market, 2021-2030” report
to its list of offerings.
Small-molecule-induced protein degradation has
been demonstrated to possess the potential to drug a broader range of proteinaceous
biological targets. It involves the selective recruitment of the body’s
inherent protein degradation pathways, to eliminate disease causing /
associated proteins, using bifunctional small molecule drugs. Presently, the
most popular and promising class of interventions in this field of research, is
proteolysis targeting chimeras (PROTACs); these can simultaneously bind a
target protein and an E3-ubiquitin ligase, and thereby, facilitate the
selective ubiquitination and eventual proteasome-mediated degradation of the
target protein. The most interesting feature of this mechanism of drug action
is the fact that PROTACs and other targeted protein degraders can eliminate protein
targets regardless of their function.
To order this 330+ page report, which
features 115+ figures and 180+ tables, please visit this link
Key Market
Insights
Presently,
more than 150 targeted protein degradation-based therapeutics are currently
under development
Around 75% of the
aforementioned candidates are in the preclinical and discovery stages, followed
by those that are being evaluated in clinical trials (25%). The these degrader
molecules are PROTAC (26), followed by DUB inhibitors (15%), protein
homeostatic modulators (14%) and SERDs/SARDs (13%).
Over
40 targeted protein degradation enabling technologies are presently available /
under development
Of these, the PROTAC®
platform is presently considered the most popular, with 15 product candidates,
developed using the same technology, under investigation. On the other hand,
there are presently 10 technologies that are designed to design / develop DUB
inhibitors.
Around 80
companies claim to be engaged in the development of targeted protein
degradation-based therapeutics
Post 2010,
there has been a notable surge in the number of companies developing targeted
protein degraders. Majority of the firms engaged in this field (57%) are based
in North America, followed by Europe (27%) and the Asia Pacific (16%).
Over
80 registered clinical trials are presently assessing targeted protein
degradation-based therapeutics, worldwide
It is
worth mentioning that most of the clinical research in this direction is being
conducted in Europe (60%), followed by North America and the Asia Pacific. However,
more than 40% of the total number of patients enrolled in such trials are in North
America.
Over 770 grants have been awarded to support research on targeted
protein degradation-based therapeutics, since 2016
An
estimate total of USD 345 million in grants have been awarded to various
organizations working in this domain, during the period between January 2016 to
December 2020. Almost 40% of the total number of grants were provided by the
National Cancer Institute.
More than
14,500 patents have been filed / granted related to targeted protein
degradation enabling technologies, since 2018
Around
50% of these intellectual property documents were filed / granted in the US;
other key regions with significant intellectual capital include Australia, China,
Japan, Canada and Korea. Leading non industry players (in terms of the size
of intellectual property portfolio) include the University of California, Massachusetts
Institute of Technology, Broad Institute, Harvard College and Dana Farber
Cancer Institute.
Partnership
activity within this domain has grown significantly between 2014 and 2021
The maximum number of partnerships for targeted
protein degradation-based therapeutics were signed in 2018. R&D agreements
(25%) and research agreements (23%) emerged as the most popular types of
partnership models adopted so far, by stakeholders in this industry.
Over USD 5 billion has been invested by both private and
public investors, since 2014
Companies involved in the development of targeted
protein degradation-based therapeutics have raised around USD 2.3 billion through
venture capital financing, which represents 43% of the total capital raised in
the given time period. Overall, more than 180 investors have actively financed
projects / initiatives in this domain.
Presently,
the market is driven by revenues from therapy development enabling technologies;
it is anticipated to grow at a CAGR of around 27%, till 2030
Over
50% of the technology licensing-related opportunity is associated with platforms
intended for drugs targeting oncological disorders; this trend is unlikely to
change in the foreseen future. North America is expected to capture over 55% of
the market share by 2030.
To request a sample copy / brochure of this
report, please visit this link
Key
Questions Answered
§
§
§
§
§
§
§
§
The USD 3.3
billion (by 2030) financial opportunity within the targeted protein degradation
enabling technologies market has been analyzed across the following segments:
§
§
§
§
§
§
§
§
§
§
- Oncological
Disorders
- Neurological
Disorders
- Others
§
§
§
§
§
§
§
§
The
research includes detailed profiles of key players (listed below); each
profile features an overview of the company, its financial information (if available),
brief descriptions of its proprietary drug(s) and an informed future outlook.
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
For additional details, please
visit
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
or email sales@rootsanalysis.com
You may also be interested in the
following titles:
2.
3.
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
